sildenafil cream (SST-6006) / Daré Biosci, Strategic Science & Technologies - LARVOL DELTA

Using Thermography to Assess the Affects of Sildenafil Cream, 3.6% (clinicaltrials.gov) - P1 | N=13 | Completed | Sponsor: Daré Bioscience, Inc. | Recruiting ➔ Completed | Trial completion date: Jul 2024 ➔ Oct 2024

Trial completion • Trial completion date • Sexual Disorders

Impact of age, race, and medication use on efficacy endpoints in a randomized controlled trial of topical sildenafil cream for the treatment of female sexual arousal disorder. (PubMed, Sex Med) - "Age and hormonal contraceptive use did not impact the efficacy of topical Sildenafil Cream. Daily psychiatric medication use decreased sexual desire in active and placebo users."

Journal • Psychiatry • Sexual Disorders

Safety of topical sildenafil cream, 3.6% in a randomized, placebo-controlled trial for the treatment of female sexual arousal disorder. (PubMed, J Sex Med) - "These data demonstrate that topically applied sildenafil cream was safe and well tolerated by exposed users and their sexual partners."

Journal • Erectile Dysfunction • Sexual Disorders

Comparisons and correlations of 1-month recall vs 24-hour recall in patient-reported outcomes of an exploratory, phase 2b, randomized, double-blind, placebo-controlled clinical trial of sildenafil cream, 3.6% for the treatment of female sexual arousal disorder. (PubMed, J Sex Med) - P2b | "These data will be used in planning future efficacy assessments of sildenafil cream for FSAD."

Clinical • Journal • P2b data • Patient reported outcomes • Sexual Disorders

Preliminary Efficacy of Topical Sildenafil Cream for the Treatment of Female Sexual Arousal Disorder: A Randomized Controlled Trial. (PubMed, Obstet Gynecol) - P2b | "Topical sildenafil cream improved outcomes among women with female sexual arousal disorder, most significantly in those who did not have concomitant orgasmic dysfunction. In particular, in an exploratory analysis of a subset of women with female sexual arousal disorder with or without concomitant decreased desire, topical sildenafil cream increased sexual arousal sensation, desire, and orgasm and reduced sexual distress."

Journal • CNS Disorders • Pain • Sexual Disorders

Using Thermography to Assess the Affects of Sildenafil Cream, 3.6% (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Daré Bioscience, Inc. | Trial completion date: Feb 2024 ➔ Jul 2024 | Trial primary completion date: Dec 2023 ➔ Apr 2024

Trial completion date • Trial primary completion date • Sexual Disorders

Using Thermography to Assess the Affects of Sildenafil Cream, 3.6% (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Daré Bioscience, Inc. | Trial primary completion date: Sep 2023 ➔ Dec 2023

Trial primary completion date • Sexual Disorders

Using Thermography to Assess the Affects of Sildenafil Cream, 3.6% (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Daré Bioscience, Inc. | Not yet recruiting ➔ Recruiting | Trial completion date: Jul 2023 ➔ Feb 2024

Enrollment open • Trial completion date • Sexual Disorders

Using Thermography to Assess the Affects of Sildenafil Cream, 3.6% (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: Daré Bioscience, Inc.

New P1 trial • Sexual Disorders

Daré Bioscience (BIO 2022) - "The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. Daré’s product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application."

Sexual Disorders • Vaginitis • Women's Health